In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients
- 138 Downloads
Technetium-99m sestamibi is a transport substrate recognised by the multidrug-resistant P-glycoprotein (Pgp). To test whether99mTc-sestamibi efflux is enhanced in breast carcinomas overexpressing Pgp, we determined the efflux rates of99mTc-sestamibi and Pgp levels in tumours from 30 patients with untreated breast carcinoma. Patients were intravenously injected with 740 MBq of99mTc-sestamibi and underwent a 15-min dynamic study followed by the acquisition of static planar images at 0.5, 1, 2 and 4 h. Tumour specimens were obtained from each patient 24 h after99mTc-sestamibi scan and Pgp levels were determined using125I-MRK16 monoclonal antibody and in vitro quantitative autoradiography. All breast carcinomas showed high uptake of99mTc-sestamibi and data from region of interest analysis on sequential images were fitted with a monoexponential function. The efflux rates of99mTc-sestamibi, calculated from decay-corrected time-activity curves, ranged between 0.00121 and 0.01690 min−1 and were directly correlated with Pgp levels measured in the same tumours (r=0.62;P<0.001). Ten out of 30 breast carcinomas (33%) contained 5 times more Pgp than benign breast lesions and showed a mean concentration of 5.73±1.63 pmol/g of tumour (group A). The remaining 20 breast carcinomas had a mean Pgp concentration of 1.29±0.64 pmol/g (group B), equivalent to that found in benign breast lesions.99mTc-sestamibi efflux from tumours of group A was 2.7 times higher than that observed in tumours of group B (0.00686±0.00390 min−1 vs 0.00250±0.00090 min−1,P<0.001). The in vivo functional test with99mTc-sestamibi showed a sensitivity and a specificity of 80% and 95%, respectively. In conclusion, the efflux rate of99mTc-sestamibi may be used for the in vivo identification of the multidrug resistant (MDR1) phenotype in untreated breast cancer patients.
Key wordsMultidrug resistance P-glycoprotein Technetium-99m sestamibi Breast carcinoma
Unable to display preview. Download preview PDF.
- 12.Wackers FJT, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusick K. Tc-99m-hexakis 2-methoxy isobutylisonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging.J Nucl Med 1989; 30: 301–311.PubMedGoogle Scholar
- 20.Hartmann WH, Ozzello L, Sobun LH, Stalsberg H.Histological typing of breast tumors, 2nd edn. Geneva: WHO, 1981.Google Scholar
- 22.EORTC Breast Cancer Cooperative Group. Standards for the assessment of hormone receptors in human breast cancer.Eur J Cancer 1980; 16: 1513–1515.Google Scholar
- 24.Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.J Nucl Med 1996; 37: 665–672.PubMedGoogle Scholar
- 31.Colton T.Statistics in medicine. Boston: Little, Brown and Co., 1974.Google Scholar
- 34.Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski, Piana L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and immunohistochemical prognostic indicators.J Natl Cancer Inst 1994; 86: 1539–1545.PubMedGoogle Scholar
- 36.Young AB, Frey KA, Agranoff BW. Receptor assay: in vitro and in vivo. In: Phelps M, Mazziotta J, Schelbert H, eds.Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press; 1986: 73–111.Google Scholar
- 37.Del Vecchio S, Stoppelli P, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.Cancer Res 1993; 53: 3198–3206.PubMedGoogle Scholar